Treatment outcomes of targeted therapy in patients with non–small cell lung cancer harboring compound mutations in the EGFR gene at the National Lung Hospital
Main Article Content
Abstract
Targeted therapy in patients with non–small cell lung cancer (NSCLC) harboring compound mutations in the EGFR gene (defined as the presence of two mutations within the same EGFR gene) has remained a clinical challenge in recent years. This study was conducted in patients with NSCLC carrying compound EGFR mutations who were treated with first- and second-generation EGFR tyrosine kinase inhibitors (EGFR-TKIs). The results showed an objective response rate (ORR) of 64%, including 2 patients (8%) with complete response and 14 patients (56%) with partial response. The disease control rate (DCR) was 92%, with 7 patients (28%) achieving stable disease and 2 patients (8%) experiencing disease progression. The mean progression-free survival (PFS) was 9.6 ± 0.7 months, with a median PFS of 9.1 months (95% CI: 8.0 – 9.7 months). The mean overall survival (OS) was 18.7 ± 1.6 months, with a median OS of 20.0 months (95% CI: 10.8 – 23.3 months). These preliminary results suggest that NSCLC patients harboring compound EGFR mutations generally still derive meaningful benefit from EGFR-TKIs, particularly when at least one classical sensitizing mutation is present.
Article Details
Keywords
Non-small cell lung cancer, NSCLC, Osimetinib, DFS, OS
References
2. B Z, S W, J Q, et al. Complex epidermal growth factor receptor mutations and their responses to tyrosine kinase inhibitors in previously untreated advanced lung adenocarcinomas. Cancer. 2018;124(11). doi:10.1002/cncr.31329
3. Li H, Wang C, Wang Z, et al. Efficacy and long-term survival of advanced lung adenocarcinoma patients with uncommon EGFR mutations treated with 1st generation EGFR-TKIs compared with chemotherapy as first-line therapy. Lung Cancer. 2019;130:42-49. doi:10.1016/j.lungcan.2019.02.001
4. Paz-Ares L, Tan EH, O’Byrne K, et al. Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial. Ann Oncol Off J Eur Soc Med Oncol. 2017;28(2):270-277. doi:10.1093/annonc/mdw611
5. Ji J, Aredo JV, Piper-Vallillo A, et al. Osimertinib in NSCLC With Atypical EGFR-Activating Mutations: A Retrospective Multicenter Study. JTO Clin Res Rep. 2023;4(3):100459. doi:10.1016/j.jtocrr.2022.100459
6. Chen M, Xu Y, Zhao J, et al. Concurrent Driver Gene Mutations as Negative Predictive Factors in Epidermal Growth Factor Receptor-Positive Non-Small Cell Lung Cancer. EBioMedicine. 2019;42:304-310. doi:10.1016/j.ebiom.2019.03.023
7. Barnet MB, O’Toole S, Horvath LG, et al. EGFR-Co-Mutated Advanced NSCLC and Response to EGFR Tyrosine Kinase Inhibitors. J Thorac Oncol Off Publ Int Assoc Study Lung Cancer. 2017;12(3):585-590. doi:10.1016/j.jtho.2016.09.001
8. Zhang Y, Li S, Lyu Z, et al. The co-mutation of EGFR and tumor-related genes leads to a worse prognosis and a higher level of tumor mutational burden in Chinese non-small cell lung cancer patients. J Thorac Dis. 2022;14(1):185-193. doi:10.21037/jtd-21-1921
9. Attili I, Passaro A, Pisapia P, Malapelle U, de Marinis F. Uncommon EGFR Compound Mutations in Non-Small Cell Lung Cancer (NSCLC): A Systematic Review of Available Evidence. Curr Oncol Tor Ont. 2022;29(1):255-266. doi:10.3390/curroncol29010024
10. Tan J, Hu C, Deng P, et al. The Predictive Values of Advanced Non-Small Cell Lung Cancer Patients Harboring Uncommon EGFR Mutations-The Mutation Patterns, Use of Different Generations of EGFR-TKIs, and Concurrent Genetic Alterations. Front Oncol. 2021;11:646577. doi:10.3389/fonc.2021.646577
11. Wang C, Zhao K, Hu S, et al. Clinical outcomes of gefitinib and erlotinib in patients with NSCLC harboring uncommon EGFR mutations: A pooled analysis of 438 patients. Lung Cancer. 2022;172:86-93. doi:10.1016/j.lungcan.2022.08.010
12. Lê Tú Linh, Lượng, Đinh V Hiếu, Đặng D Trang, và cs. (2024). Ung thư phổi không tế bào nhỏ có đồng thời đột biến gen EGFR và PIK3CA: Kết quả điều trị bước đầu tại Bệnh viện Phổi Trung ương giai đoạn 2022-2024. Tạp chí Y học Cộng đồng. 2024;65.
13. Lê Tú Linh, Nguyễn Đoan Trang, Đặng Huy Hiếu, và cs. Kết quả điều trị biến thể gen Del19/L858R trên bệnh nhân ung thư phổi mang đồng thời đột biến EGFR và đột biến gen khác. Tạp chí Nghiên cứu Y học. 2025;191(6), 12-20.
14. Nguyễn Thị Thái Hòa, Nguyễn Thị Phương Hoa (2021). Kết quả điều trị ung thư phổi không tế bào nhỏ có đột biến EGFR hiếm bằng thuốc ức chế tyrosine kinase (tkis) thế hệ 1 và 2. Tạp chí Y học Việt Nam. 2021;501(2).